Education
About Us
Working with TipRanks
Follow Us
Elanco Animal Health (ELAN)
NYSE:ELAN
Top Page
Elanco Animal Health
(NYSE:ELAN)
Select Model
Select Model
Rating:58Neutral
Price Target:
$26.00
▲(3.50% Upside)
Action:ReiteratedDate:03/18/26
The score is driven primarily by stable cash generation and improving leverage trends, supported by a constructive 2026 outlook from management. Offsetting factors are inconsistent GAAP profitability (negative P/E) and weak near-term technical momentum (negative MACD, sub-50 RSI).
Positive Factors
Innovation Revenue Growth
A clear increase and upward guidance for innovation revenue signals durable portfolio innovation and successful commercialization of higher‑value products. Sustained innovation revenue growth supports margin expansion, higher-quality revenue mix, and long-term organic growth independent of cyclical end markets.
Strong New Product Adoption
Rapid clinic penetration and high reorder rates on recent launches indicate durable competitive advantages in go‑to‑market and product efficacy. Strong adoption creates recurring revenue streams, cross‑sell uplift across portfolios, and entrenches vet/distributor relationships that sustain growth over multiple years.
Improving Cash Generation & Deleveraging
Consistent positive operating cash flow and an explicit deleveraging plan enhance financial flexibility. Ongoing FCF, combined with management targets to reduce net leverage, supports sustained R&D, launches, and M&A optionality while lowering interest burden over the medium term.
Negative Factors
Profitability Volatility
Swinging GAAP profitability and inconsistent ROE indicate earnings quality risk. Profit volatility can constrain reinvestment, increase capital costs, and weaken ability to consistently generate shareholder returns, making long‑term planning and valuation of pipeline outcomes more uncertain.
Manufacturing Capacity Constraints
Operational limits on mAb manufacturing create a structural headwind for converting pipeline approvals into revenue. Phased launches and ramp constraints can delay peak sales, slow margin improvement, and require capital expenditure or third‑party reliance, raising execution risk over multiple quarters.
Elevated Leverage & Interest Cost Sensitivity
Despite improvement, leverage remains material and interest costs have risen, reducing free cash available for growth or buybacks. Elevated leverage limits strategic flexibility, increases sensitivity to cash flow swings from launches or margins, and prolongs the time to reach investment‑grade stability.
Elanco Animal Health (ELAN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$12.49B
Dividend YieldN/A
Average Volume (3M)4.67M
Price to Earnings (P/E)―
Beta (1Y)1.38
Revenue Growth3.08%
EPS Growth-82.39%
CountryUS
Employees9,000
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.13
Shares Outstanding497,168,100
10 Day Avg. Volume4,869,944
30 Day Avg. Volume4,673,270
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)1.72
Price to Sales (P/S)2.38
P/FCF Ratio39.55
Enterprise Value/Market Cap1.26
Enterprise Value/Revenue3.33
Enterprise Value/Gross Profit7.16
Enterprise Value/Ebitda21.72
Forecast
1Y Price Target
$29.40Price Target Upside17.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)1.03
Revenue Forecast (FY)$5.00B
Elanco Animal Health Business Overview & Revenue Model
Company DescriptionElanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
How the Company Makes MoneyElanco makes money primarily by selling animal health products, generating revenue when its products are purchased through veterinary clinics, distributors, retailers, and livestock/agricultural channels. Its revenue model is centered on two main end-markets: (1) Companion animal, where sales are driven by branded therapeutics such as parasiticides and other veterinary products used in pets; demand is influenced by pet ownership trends, veterinary visit volumes, product efficacy/safety profiles, and brand adoption by veterinarians and pet owners. (2) Farm animal (food-producing animals), where sales come from products such as vaccines, anti-infectives, parasiticides, and other solutions used in cattle, swine, poultry, and other livestock; demand is influenced by herd/flock health needs, production economics, disease prevalence, and producer adoption through integrated livestock systems and distributors. Across both segments, Elanco monetizes its R&D and regulatory capabilities by developing proprietary products (including line extensions and lifecycle management), manufacturing at scale, and commercializing through direct sales forces and third-party distributors. The company’s earnings are supported by its product mix (higher-value innovative brands versus more mature products), geographic expansion, pricing and volume dynamics, and the ability to maintain market access through regulatory approvals and, where applicable, intellectual property protection. Specific material partnerships or licensing arrangements contributing to revenue: null.
Elanco Animal Health Earnings Call Summary
Earnings Call Date:Feb 24, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 13, 2026
Earnings Call Sentiment Positive
The call conveyed broad positive momentum: strong product launches (Credelio Quattro, ZENRELIA), meaningful innovation revenue growth, share gains across multiple categories, improved deleveraging, and raised innovation guidance for 2026. Headwinds include higher taxes impacting EPS, lower Q4 operating cash due to one‑time tax timing, inflation and inventory cost flow‑through pressuring near‑term gross margin, and manufacturing ramp constraints for mAb launches. Management provided upbeat 2026 guidance aligned with their long‑term algorithm and emphasized productivity initiatives to support margins.Q4-2025 Updates
Positive Updates
Strong Q4 and Full-Year Organic Revenue Growth
Q4 2025 organic constant currency revenue growth of 9%; full-year 2025 organic constant currency revenue growth of 7%; reported Q4 revenue $1,140M (+12% YoY) and full-year reported revenue $4,715M (+6% YoY).
Innovation Revenue Outperformed and 2026 Raise
2025 innovation revenue of $892M (largest quarter for innovation in Q4); company raised 2026 innovation outlook to $1,150M (commitment to at least +$250M growth versus 2025).
Broad Product Momentum — Credelio Quattro
Credelio Quattro described as fastest blockbuster in company history; major U.S. broad‑spectrum endectocide market grew ~30% YoY and Quattro is gaining clinic share (≈1/3 of clinics penetrated) with strong Puppy Index performance and meaningful portfolio uplifts to other products.
Broad Product Momentum — ZENRELIA
ZENRELIA delivered double‑digit JAK market share in several international markets (e.g., Brazil ~40%, Japan >30%), ~50% clinic penetration in the U.S., >80% reorder rate, and notable early traction in Europe, UK, and Australia.
Other High-Impact Launches and Growth
Bifrenna received USDA approval (Dec 31) and is planned for phased 2026 launch; OTC AdTab sales up >50%, becoming #1 oral OTC in Europe; Experior up 35% in Q4 and crossed $200M in 2025 (nearly +80% YoY for the year).
Strong Farm and Pet Health Performance
Q4 US farm animal +17% and US pet health +10% (Q4); international pet health +8% and international farm animal +4% on organic constant currency basis.
Financial Execution — EBITDA, EPS, and Deleveraging
Q4 adjusted EBITDA $189M (+7% YoY); full-year adjusted EBITDA $901M; full-year adjusted EPS $0.94 vs $0.91 in 2024. Net leverage improved to 3.6x at year-end with target 3.1–3.3x for 2026 and path to <3x in 2027.
2026 Guidance in Line with Long-Term Algorithm
2026 guidance: organic constant currency revenue growth 4–6% (revenue $4,950–$5,020M), adjusted EBITDA $955–$985M (~+8% at midpoint), adjusted EPS $1.00–$1.06 (~+10% at midpoint), and gross margin expansion expected ~+40 bps.
Operational Productivity Initiatives
Elanco Ascend productivity program underway; restructuring expected to generate ~$25M in savings in 2026 and support margin expansion while funding launches and R&D.
Strategic M&A and Pipeline
Signed agreement to acquire AHV International (dutch farm-animal innovator) to expand dairy portfolio; R&D engine targeting five-to-six potential blockbuster approvals through 2031 and Big Six expected to double from 2025 to 2028.
Negative Updates
Q4 Adjusted EPS Decline and Higher Tax Rate
Q4 adjusted EPS was $0.13, down 7% YoY; full-year effective tax rate increased to 21.8% (up ~370 basis points YoY), with higher tax timing impacting quarterly EPS.
Weaker Cash from Operations in Q4
Cash generated from operations in Q4 was $108M versus $177M in prior year (decline driven by expected cash tax payments related to 2024 Aqua divestiture, partially offset by working capital improvements).
Inventory and Inflationary Pressure on Margins
Adjusted gross margin was flat YoY at 54.9% for the full year; company cited inflationary pressures and flow‑through of higher inventory costs, with first‑half 2026 gross margin expected to decline year over year before improvement.
Interest Expense and Expiration of Swap Benefit
Quarterly interest expense was $47M (+2% YoY); expiration of a favorable interest rate swap amortization benefit in 2025 increased interest costs versus prior favorable period.
Manufacturing Ramp Constraints for mAb Launches
Bifrenna launch will be phased as manufacturing capacity (bioreactors) is ramped; scaling mAb production is a noted operational constraint that may limit near‑term commercialization cadence.
Competitive and Market Headwinds
Guidance recognizes competitive pressures including generics and new entrants; management flagged need to remain responsive to competitive responses which could moderate near‑term growth.
Leverage and Net Debt Level
Net debt ended the quarter at approximately $3.2B with net leverage 3.6x — improved versus prior but still elevated and targeted to reach 3.1–3.3x in 2026 and sub‑3x in 2027.
Conservative 2026 Guidance Relative to Recent Momentum
Analyst questions noted guidance appears conservative given strong late‑2025 momentum, accelerated pricing expectations, and continued product ramp — management maintained guidance consistent with Investor Day algorithm reflecting prudent assumptions.
Company Guidance
Elanco’s 2026 guidance calls for full‑year organic constant‑currency revenue growth of 4%–6% (revenue $4,950–$5,020M), adjusted EBITDA $955–$985M (≈+8% at the midpoint), and adjusted EPS $1.00–$1.06 (≈+10% at the midpoint); innovation revenue is raised to $1,150M (≥+$250M vs. 2025’s $892M), gross margin is expected to improve ~40 bps, OpEx to grow ~7%, and Elanco Ascend and restructuring are expected to deliver ~$25M of savings in 2026; Q1 guidance is organic cc growth 4%–6% (revenue $1,280–$1,305M), adjusted EBITDA $290–$310M (≈+9% at the midpoint) and adjusted EPS $0.33–$0.36; balance‑sheet targets include reducing net leverage from 3.6x at year‑end 2025 to 3.1–3.3x by year‑end 2026 (AHV acquisition not included in guidance; close expected in Q2 with modest 2026 contribution) and a long‑term leverage goal of 2.0–2.5x with a path to sub‑3x in 2027.Elanco Animal Health Financial Statement Overview
Summary
Cash generation is a relative strength (positive operating cash flow in 2024–2025 and positive 2025 free cash flow), and leverage is improving (debt-to-equity down to ~0.61 in 2025). However, earnings quality is uneven with a return to net losses in 2025 and inconsistent ROE, which limits the score.Income Statement
Revenue has been relatively flat over the past several years, with a modest pickup in 2025 (annual revenue up to ~$4.7B). Profitability is volatile: the company swung from a solid profit in 2024 (positive net margin) back to a loss in 2025 (negative net margin), and it also posted a large loss in 2023. A clear positive is the sharp improvement in gross margin in 2025 versus prior years, but bottom-line consistency remains the key weakness.48
Neutral
Balance Sheet
Leverage looks manageable but meaningful: debt-to-equity improved to ~0.61 in 2025 from higher levels in 2023–2024, suggesting some balance sheet de-risking. Equity remains sizable relative to assets, but returns to shareholders are inconsistent, with negative return on equity in 2025 (following a positive 2024). Overall, the balance sheet is improving on leverage, but profitability-driven capital efficiency is still a risk.56
Neutral
Cash Flow
Cash generation is a relative strength: operating cash flow remained solid in 2024–2025 (~$0.54–$0.56B) and free cash flow stayed positive in 2025 (~$0.28B) despite the reported net loss. However, free cash flow declined materially in 2025 versus 2024 (negative growth), and cash conversion versus earnings is not consistently strong across years, highlighting some underlying volatility.62
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 4.71B | 4.44B | 4.42B | 4.41B | 4.76B |
| Gross Profit | 2.05B | 1.91B | 1.94B | 1.97B | 2.08B |
| EBITDA | 676.00M | 1.49B | -224.00M | 866.00M | 409.00M |
| Net Income | -232.00M | 338.00M | -1.23B | -78.00M | -483.00M |
Balance Sheet | |||||
| Total Assets | 13.36B | 12.61B | 14.36B | 15.49B | 16.48B |
| Cash, Cash Equivalents and Short-Term Investments | 545.00M | 468.00M | 352.00M | 345.00M | 638.00M |
| Total Debt | 4.02B | 4.32B | 5.77B | 5.84B | 6.32B |
| Total Liabilities | 6.81B | 6.52B | 8.14B | 8.20B | 8.97B |
| Stockholders Equity | 6.55B | 6.10B | 6.22B | 7.29B | 7.51B |
Cash Flow | |||||
| Free Cash Flow | 284.00M | 394.00M | 117.00M | 268.00M | 286.00M |
| Operating Cash Flow | 560.00M | 541.00M | 271.00M | 452.00M | 483.00M |
| Investing Cash Flow | -279.00M | 1.16B | -169.00M | -179.00M | -530.00M |
| Financing Cash Flow | -275.00M | -1.49B | -83.00M | -549.00M | 210.00M |
Elanco Animal Health Technical Analysis
Positive
25.12
Price Trends
24.56
Positive
23.37
Positive
20.12
Positive
Market Momentum
-0.11
Negative
54.93
Neutral
83.55
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ELAN, the sentiment is Positive. The current price of 25.12 is above the 20-day moving average (MA) of 24.67, above the 50-day MA of 24.56, and above the 200-day MA of 20.12, indicating a bullish trend. The MACD of -0.11 indicates Negative momentum. The RSI at 54.93 is Neutral, neither overbought nor oversold. The STOCH value of 83.55 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ELAN.
Elanco Animal Health Risk Analysis
Elanco Animal Health disclosed 46 risk factors in its most recent earnings report. Elanco Animal Health reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Elanco Animal Health Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | $48.96B | 20.87 | 58.23% | 1.69% | 2.68% | 11.51% | |
74 Outperform | $2.13B | 13.79 | 30.81% | 1.28% | 33.71% | 289.48% | |
70 Outperform | $11.43B | 21.72 | 16.00% | 0.64% | 10.63% | 6.35% | |
61 Neutral | $34.09B | 25.43 | 20.09% | ― | -0.25% | ― | |
58 Neutral | $12.49B | -48.42 | -3.51% | ― | 3.08% | -82.39% | |
56 Neutral | $15.54B | -4.15 | -22.99% | 3.99% | -6.40% | -320.23% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
ELAN
Elanco Animal Health
25.12
14.59
138.56%
RDY
Dr Reddy's Laboratories
14.14
0.50
3.66%
VTRS
Viatris
13.50
4.76
54.43%
TEVA
Teva Pharmaceutical
29.44
13.34
82.86%
ZTS
Zoetis
115.99
-44.70
-27.82%
PAHC
Phibro Animal Health
52.38
30.77
142.37%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.